Squamous Cell Carcinoma Quotes

The evidence reviewed suggested no increase in risk of recurrence with MHT in women with early-stage endometrial cancer; squamous cell carcinoma of the cervix or adenocarcinoma of the cervix (cervical cancer); or vaginal or vulvar cancer. Evidence also showed no adverse effect on survival rates with hormone therapy in women with epithelial ovarian cancer. On women with a history of breast cancer, their conclusion was that it should be a contraindication to the use of systemic MHT.